Ono Pharmaceutical Co Ltd (OPHLY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Ono Pharmaceutical Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Ono Pharmaceutical Co Ltd (OPHLY) has returned 16.26% so far this year and 49.86% over the past 12 months. Over the last ten years, OPHLY has returned -8.71% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Oct 1, 2012, OPHLY's average daily return is +0.03%, while the average monthly return is +0.65%. At this rate, your investment would double in approximately 8.9 years.

Historically, 51% of months were positive and 49% were negative. The best month was May 2013 with a return of +22.5%, while the worst month was Apr 2018 at -28.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, OPHLY closed higher 43% of trading days. The best single day was May 7, 2013 with a return of +22.5%, while the worst single day was Aug 5, 2016 at -18.0%.

Ono Pharmaceutical Co Ltd has an annualized alpha of 4.07%, beta of 0.33, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since October 02, 2012.

• This stock participated in 42.67% of S&P 500 Index downside but only 28.62% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.33 may look defensive, but with R² of 0.03 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

OPHLY ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Ono Pharmaceutical Co Ltd (OPHLY) and compare them to a chosen benchmark (S&P 500 Index).

Ono Pharmaceutical Co Ltd provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Ono Pharmaceutical Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ono Pharmaceutical Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ono Pharmaceutical Co Ltd was 80.82%, occurring on Feb 12, 2025. The portfolio has not yet recovered.

The current Ono Pharmaceutical Co Ltd drawdown is 68.08%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ono Pharmaceutical Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ono Pharmaceutical Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.